Showing 301-310 of 7665 results for "".
- Vacation Tanning Linked to Acute Changes in Skin Microbiomehttps://practicaldermatology.com/news/vacation-tanning-linked-to-acute-changes-in-skin-microbiome/2461912/Sun-seeking behaviors while on vacation may affect the skin’s microbiome, new research suggests. Prior to vacations to sunny destinations, which lasted at least seven days, the researchers analyzed participants’ skin. On day one, 28, and 84 post-holiday, participants’ skin microbiota was assessed …
- Skin Cancer-related Mutations Higher in the UK Than Singaporehttps://practicaldermatology.com/news/skin-cancer-related-mutations-higher-in-the-uk-than-singapore/2461909/People in the UK have facial skin that is far more DNA damaged from the sun than people in Singapore, explaining the far higher risk of developing basal and squamous cell carcinomas in the UK, new research suggests. When researchers from the Wellcome Sanger Institute and their collaborators at the…
- Another FDA Nod for SkinStylus Microneedling Device: Facial Acne Scarshttps://practicaldermatology.com/news/another-fda-nod-for-skinstylus-microneedling-device-facial-acne-scars/2461904/The U.S. Food and Drug Administration (FDA) has cleared The Beauty Health Company’s SkinStylus microneedling device for use on facial acne scarring in Fitzpatrick skin types I, II, and III in patients aged 22 years and older. SkinStylus is already FDA-cleared to improve the appearance of surgical …
- Abeona Therapeutics Submits Briefing Package for Pre-BLA Meeting with FDA in August 2023https://practicaldermatology.com/news/abeona-therapeutics-submits-briefing-package-for-pre-bla-meeting-with-fda-in-august-2023/2461901/Abeona Therapeutics Inc. completed the submission of the briefing package to the U.S. Food and Drug Administration (FDA) for the Company’s pre-Biologics License Application (BLA) meeting in August 2023. The purpose of the meeting is to discuss the format, content, and acceptability of the anticip…
- US FDA Grants Breakthrough Device Designation to Marpe's Dermatology Screening Systemhttps://practicaldermatology.com/news/us-fda-grants-breakthrough-device-designation-to-marpes-dermatology-screening-system/2461900/The US Food and Drug Administration (FDA) has granted Breakthrough Device designation to Marpe Technologies full-body Dermatology Screening System. The Marpe System is designed to acquire and analyze total body images to support the identification of malignant and pre-malignant lesions, with a par…
- Reinforcement Learning Model May Boost AI Skin Cancer Diagnosis Accuracyhttps://practicaldermatology.com/news/reinforcement-learning-model-may-boost-ai-skin-cancer-diagnosis-accuracy/2461897/Artificial intelligence (AI) is already being used to diagnose skin cancer, but so far, it can’t keep pace with the complex decision-making of doctors in practice. Now, an international research team is developing a learning method in which greater accuracy in AI results can be achieved by incorpo…
- More Screening Won’t Solve Racial Disparities in Melanoma Outcomeshttps://practicaldermatology.com/news/more-screening-wont-solve-racial-disparities-in-melanoma-outcomes/2461894/Increased skin cancer screening in individuals with skin of color is not sufficient to address racial disparities in melanoma survival rates, according to a new study in JAMA Dermatology. “In this study, we asked whether screening could address this disparity by helping detect melanoma early,” say…
- Merck, Moderna Initiate Phase 3 Study of V940-KEYTRUDA Combo for Adjuvant Treatment of Resected High-risk Melanomahttps://practicaldermatology.com/news/merck-moderna-initiate-phase-3-study-of-v940-mrna-4157-in-combination-with-keytruda-for-adjuvant-treatment-of-patients-with-resected-high-risk-melanoma/2461890/Merck today announced the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-ri…
- Research Validates Atopic March Patternhttps://practicaldermatology.com/news/research-validates-the-atopic-march/2461889/New research validates a population-level pattern of the “allergic march” in which allergies first present as eczema, followed by food allergies, asthma, and environmental allergies. The average peak age of onset was approximately four months for eczema, 13 months for anaphylactic food allergies,…
- Network Meta-analysis: Oral Isotretinoin Is the Most Effective Acne Treatmenthttps://practicaldermatology.com/news/network-meta-analysis-oral-isotretinoin-is-the-most-effective-acne-treatment/2461888/Oral isotretinoin, followed by topical antibiotic, benzoyl peroxide and retinoid, are most effective acne treatments, according to a network meta-analysis of 221 randomized controlled trials. For the study, researchers investigated the effectiveness of various pharmacological therapies for acne vu…